Raloxifene - adverse reactions. Part 2
The general adverse reactions which as believe, have been connected with therapy raloxifene, were hot flashes and foot spasms.
Hot flashes have occurred in approximately each 10th patient on Raloxifene and were usually informed during the first
6 months of processing also did not differ from placebo after that. Foot spasms have occurred in approximately everyone 14th
Patients on EVISTA.
Operated placebo Clinical tests of Prevention Osteoporosis — safety raloxifene has been estimated
First of all in 12 Phases 2 and the Phase 3 studies with placebo, an estrogen, and control groups of therapy progestin an estrogen.
With 2 till 30 months duration of processing fluctuated, and 2036 women have been exposed raloxifene HCl
(371 patient has received 10 - 50 mg/days, 828 has received 60 mg/days, and 837 received from 120 to 600 mg/days).
Therapy has been stopped because of adverse reaction in 11.4 % from 581 EVISTA-considered women and
12.2 % 584 considered placebo women. Norms of the termination because of hot flashes did not differ considerably between
EVISTA and groups placebo (1.7 % and 2.2 %, accordingly).
The general adverse reactions which as believe, have been connected with a preparation, were hot flashes and foot spasms. Hot flashes
Occurred in approximately every fourth patient on EVISTA against approximately every sixth on placebo. The first occurrence of the hot
On flashes have usually informed within the first 6 months of processing.
The table 1 lists the adverse reactions occurring either in osteoporosis to processing or in five placebo of prevention -
Operated clinical tests in frequency of 2.0 % in any group and in EVISTA more-considered women than in
Considered placebo women. Adverse reactions show without causal relationship attributing. The majority of the adverse
The reactions occurring during researches, were moderate and at all the therapy termination did not demand.
Tags: Evista, menopausal problems, osteoporosis, Raloxifene
Leave a Reply